Scholars@Duke
Allison Taylor

Selected Publications

In patients with suspected thrombotic thrombocytopenic purpura, what is the optimal time to therapeutic plasma exchange?

Journal Article Hematol Transfus Cell Ther · December 12, 2025 BACKGROUND: In patients with suspected immune thrombotic thrombocytopenic purpura, guidelines suggest that therapeutic plasma exchange should be initiated within eight hours. However, this time threshold may be difficult to attain. This study sought to ide ... Full text Link to item Cite

Top Ten Tips Palliative Care Clinicians Should Know About Caring for Patients with Myeloproliferative Neoplasms.

Journal Article J Palliat Med · February 2025 Myeloproliferative neoplasms (MPNs) are a group of rare chronic progressive blood cancers that vary widely in clinical presentation, yet all patients have a risk of disease progression and thrombotic complications. Diseases include primary myelofibrosis, p ... Full text Link to item Cite

Adverse Childhood Experiences Are Associated With an Increased Risk of Dyspepsia in Patients Undergoing Upper Endoscopy.

Journal Article Gastro Hep Adv · 2025 BACKGROUND AND AIMS: Stress is a risk factor for dyspepsia; however, neither the type nor timing of stress exposures across the lifespan in this syndrome are well understood. We aimed to understand the association between both adverse childhood experiences ... Full text Link to item Cite

Protocol for a scoping review of time to treatment in adults with newly diagnosed multiple myeloma.

Journal Article PloS one · January 2025 BackgroundDelays in cancer treatment can result in tumor growth, increased clonal heterogeneity, upstaging, increased symptoms, organ damage, increased psychological distress, and worse clinical outcomes. Evidence supported guidelines for treatmen ... Full text Cite

Treatment of Relapsed/Refractory t(11;14) Multiple Myeloma and High-Risk Myelodysplastic Syndrome With Venetoclax.

Journal Article Case Rep Hematol · 2025 Patients with multiple myeloma (MM) have an inherent risk for secondary myeloid malignancies. Innovative approaches to treatment are needed when these hematologic malignancies co-occur. Venetoclax (VEN), a BCL2 inhibitor, has been used in combination with ... Full text Link to item Cite

Treatment Experience of Patients with Acute Myeloid Leukemia in the Era of Novel Therapies: A Longitudinal Electronic Patient-Reported Outcomes Study

Conference Blood · November 5, 2024 Background: Since 2017, novel therapies for acute myeloid leukemia (AML) have emerged as options for patients unfit for high-intensity induction chemotherapy. However, much of our current ... Full text Cite

Clinician Adherence to Screening and Preventive Practices for Non-Malignant Late Effects Among Allogeneic Hematopoietic Cell Transplant Survivors in the United States

Conference Blood · November 5, 2024 Background: Survivors of allogeneic hematopoietic cell transplantation (HCT) are at risk for treatment-related late effects. Published recommendations for screening/prevention of late com ... Full text Cite

Real-World Clinician Adherence to Screening and Preventive Practices Guidelines for Subsequent Neoplasms Among Allogeneic Hematopoietic Cell Transplant Survivors in the United States

Conference Blood · November 5, 2024 Background: Prior studies have reported variable adherence to screening/prevention guidelines from allogeneic hematopoietic cell transplant (HCT) survivors' perspective (Khera N et al. Bi ... Full text Cite

Survival Outcomes in Older Adult Acute Lymphoblastic Leukemia Patients Analyzed by Facility Volume and Type: A National Cancer Database Analysis.

Journal Article Cancer reports (Hoboken, N.J.) · August 2024 BakgroundIt is important to understand the outcomes of adult acute lymphoblastic leukemia (ALL) patients at different facilities as treatment paradigms change.AimsOur primary objective was to determine adult ALL overall survival (OS) by f ... Full text Cite

Influence of Income, Education, and Medicaid Expansion on Palliative Care in Acute Myeloid Leukemia Using the National Cancer Database.

Journal Article Journal of pain and symptom management · April 2024 Palliative care is integral to symptom management, and we examined its relationship with income, education, and Medicaid expansion in acute myeloid leukemia. This was a retrospective cross-sectional study using the National Cancer Database that included pa ... Full text Cite

Hospital facility characteristics and socioeconomic factors on outcomes and treatment in patients with multiple myeloma: National Cancer Database analysis.

Journal Article Annals of hematology · June 2023 Previous studies have shown that socioeconomic factors play an important role in multiple myeloma (MM) health outcomes. We postulated that the type of treatment facilities and their volume of cases also affect overall survival, utilization of various thera ... Full text Cite

Hypoalbuminemia as a prognostic biomarker for higher mortality and treatment complications in acute myeloid leukemia.

Journal Article Hematological oncology · December 2021 Older age and poor performance status lead to worse outcomes in acute myeloid leukemia (AML) patients. Hypoalbuminemia is a negative predictor of morbidity and mortality in several malignancies. We evaluated the relationship between baseline serum albumin ... Full text Cite

Impact of Treating Facility on Overall Survival and Treatment in Multiple Myeloma (MM) Using National Cancer Database (NCDB)

Conference Blood · November 5, 2021 AbstractIntroduction:Prior studies have shown poorer outcomes in Black and Hispanic patients and in patients with lower median household income and education 1-5. In MM, we h ... Full text Cite

Impact of Treatment Facility Chracteristics on Patient (Pt) Outcomes in Acute Myeloid Leukemia (AML) Using Data from the National Cancer Database (NCDB)

Conference Blood · November 5, 2020 IntroductionThe literature suggests a widespread reduction in the availability and accessibility of newer treatment options among marginalized groups in AML. Studies from large national databases point to lower soci ... Full text Cite

Rational design of a trimeric APRIL-based CAR-binding domain enables efficient targeting of multiple myeloma.

Journal Article Blood advances · November 2019 Chimeric antigen receptor (CAR) T cells (CARTs) have shown tremendous potential for the treatment of certain B-cell malignancies, including patients with relapsed/refractory multiple myeloma (MM). Targeting the B-cell maturation antigen (BCMA) has produced ... Full text Cite